By using large‐scale public data sets, we validated that ARID2 knock‐out could lead to similar molecular changes in vivo and, moreover, observed a higher number of somatic mutations in ARID2‐mutated subtypes than in the ARID2 wild‐type across various types of cancers including HCC (Figure 6B). The gene discussed is ARID2; the disease is hepatocellular carcinoma.